PLoS Pathogens · 2015 · 57 citations · 50 references
Life SciencesImmunologyInfectious DiseasesImmunizationMolecular VirologyVirologyAntibody-mediated ProtectionAntiviral ImmunityAntiviral TherapyImmunopathology Of Infectious DiseasesViral InfectionsViral VaccinesAnti-viral ImmunityAntibodiesAntibody-mediated Viral NeutralizationAntibody-mediated Virus NeutralizationCross-reactive AntigensCross-reactive ImmunityEbola VaccinesMarburg Virus Disease
The filoviruses, which include the marburg- and ebolaviruses, have caused multiple outbreaks among humans this decade. Antibodies against the filovirus surface glycoprotein (GP) have been shown to provide life-saving therapy in nonhuman primates, but such antibodies are generally virus-specific. Many monoclonal antibodies (mAbs) have been described against Ebola virus. In contrast, relatively few have been described against Marburg virus. Here we present ten mAbs elicited by immunization of mice using recombinant mucin-deleted GPs from different Marburg virus (MARV) strains. Surprisingly, two of the mAbs raised against MARV GP also cross-react with the mucin-deleted GP cores of all tested ebolaviruses (Ebola, Sudan, Bundibugyo, Reston), but these epitopes are masked differently by the mucin-like domains themselves. The most efficacious mAbs in this panel were found to recognize a novel "wing" feature on the GP2 subunit that is unique to Marburg and does not exist in Ebola. Two of these anti-wing antibodies confer 90 and 100% protection, respectively, one hour post-exposure in mice challenged with MARV.
50
Ebola virus entry requires the cholesterol transporter Niemann–Pick C1
Jan E. Carette, Matthijs Raaben, Anthony Wong et al. · Nature · 2011 · 1.3K citations · Full text
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Xiangguo Qiu, Gary Wong, Jonathan Audet et al. · Nature · 2014 · 996 citations